New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
He has been associated with the Zydus Group since 2009
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Subscribe To Our Newsletter & Stay Updated
